MARKET

ARNA

ARNA

Arena Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

44.54
+1.54
+3.58%
After Hours: 44.54 0 0.00% 16:56 03/27 EDT
OPEN
41.52
PREV CLOSE
43.00
HIGH
45.80
LOW
41.25
VOLUME
967.50K
TURNOVER
--
52 WEEK HIGH
64.48
52 WEEK LOW
32.95
MARKET CAP
2.24B
P/E (TTM)
5.83
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ARNA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ARNA stock price target is 67.60 with a high estimate of 80.00 and a low estimate of 56.00.

EPS

ARNA News

More
  • Arena Pharmaceuticals: Buy The Dip Ahead Of Catalyst-Rich 2020 And 2021
  • Seeking Alpha - Article · 03/18 21:40
  • Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • PR Newswire · 03/18 21:01
  • The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
  • Benzinga · 03/12 11:37
  • The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index
  • Benzinga · 03/10 13:19

Industry

Biotechnology & Medical Research
-2.44%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About ARNA

Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The Company's drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The Company's programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s).
More

Webull offers kinds of Arena Pharmaceuticals, Inc. stock information, including NASDAQ:ARNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARNA stock news, and many more online research tools to help you make informed decisions.